学会抄録

Rationale for STARD 2015 items. (DOCX 45 kb

Additional file 3: of Evaluations of the uptake and impact of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) Statement and extensions: a scoping review

Summary across reports of SRs adhering to the PRISMA Statement. (DOCX 17 kb

Kaplan–Meier curves with 95% confidence interval for sample of 101 reviews at first update.

<p>Kaplan–Meier curves with 95% confidence interval for sample of 101 reviews at first update.</p

Kaplan–Meier curves for reviews with and without additional trials at first update.

<p>Kaplan–Meier curves for reviews with and without additional trials at first update.</p

Time to first update of the 101 updated reviews, by review team.

<p>Time to first update of the 101 updated reviews, by review team.</p

Additional file 2: of Quality of conduct and reporting in rapid reviews: an exploration of compliance with PRISMA and AMSTAR guidelines

Included and Excluded Study Lists. Details the sample of rapid reviews included in this manuscript and reports excluded studies. (DOCX 27 kb

Characteristics of updated reviews at first update period (101 reviews).

<p>*For 76 reviews that included new trials.</p

Flow diagram of selection of reviews for analysis.

<p>Flow diagram of selection of reviews for analysis.</p

Characteristics of updated reviews that included additional trials at first update (76 reviews).

<p>Characteristics of updated reviews that included additional trials at first update (76 reviews).</p

Recommended steps for developing a health research reporting guideline.

a<p>Core items (see text).</p